PALISADE BIO, INC. - Common Stock, par value $0.01 per share (PALI)
CUSIP: 696389402
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.01 per share
- Shares outstanding
- 159,058,879
- Total 13F shares
- 84,610
- Share change
- -175,983
- Total reported value
- $57,544
- Price per share
- $0.68
- Number of holders
- 11
- Value change
- -$119,036
- Number of buys
- 5
- Number of sells
- 6
Quarterly Holders Quick Answers
What is CUSIP 696389402?
CUSIP 696389402 identifies PALI - PALISADE BIO, INC. - Common Stock, par value $0.01 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 696389402:
Top shareholders of PALI - PALISADE BIO, INC. - Common Stock, par value $0.01 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Yuma Regional Medical Center |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,814,375
|
$925,331 | — | 19 Aug 2021 | |
| ARMISTICE CAPITAL, LLC |
13F
13D/G
|
Company |
5%
from 13D/G
|
144,764
|
$98,555 | — | 31 Mar 2025 | |
| Thomas Hallam |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
137,592
mixed-class rows
|
$29,372 | — | 16 Aug 2022 | |
| UBS Group AG |
13F
|
Company |
0.02%
|
38,083
|
$25,934 | — | 31 Mar 2025 | |
| Marex Group plc |
13F
|
Company |
0.02%
|
35,759
|
$24,345 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.02%
|
24,732
|
$16,837 | — | 31 Mar 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.01%
|
18,264
|
$12,000 | — | 31 Mar 2025 | |
| Virtu Financial LLC |
13F
|
Company |
0.01%
|
15,255
|
$10,000 | — | 31 Mar 2025 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
0.01%
|
14,153
|
$9,635 | — | 31 Mar 2025 | |
| Michael John Dawson |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
15,000
|
$7,650 | — | 29 Mar 2022 | |
| Cristina Csimma |
3/4/5
|
Director |
—
mixed-class rows
|
19,742
mixed-class rows
|
$5,609 | — | 08 Feb 2024 | |
| Stephanie Diaz |
3/4/5
|
Director |
—
mixed-class rows
|
19,680
mixed-class rows
|
$5,582 | — | 08 Feb 2024 | |
| James R. Neal |
3/4/5
|
Director |
—
mixed-class rows
|
17,800
mixed-class rows
|
$4,762 | — | 09 Feb 2024 | |
| Robert J. Trenschel |
3/4/5
|
Director |
—
mixed-class rows
|
17,800
mixed-class rows
|
$4,762 | — | 08 Feb 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
4,570
|
$3,111 | — | 31 Mar 2025 | |
| Mary Ann Gray |
3/4/5
|
Director |
—
mixed-class rows
|
12,700
mixed-class rows
|
$2,968 | — | 21 Nov 2023 | |
| Robert Curtis McRae |
3/4/5
|
Chief Operating Officer |
—
mixed-class rows
|
2,588
mixed-class rows
|
$1,320 | — | 03 Apr 2023 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
628
|
$428 | — | 31 Mar 2025 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
0%
|
100
|
$68 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
23
|
$16 | — | 31 Mar 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
21
|
$14 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0%
|
6
|
$4 | — | 31 Mar 2025 | |
| Margery B. Fischbein |
3/4/5
|
Director |
—
class O/S missing
|
2,100
|
— | — | 11 Jul 2024 |
Institutional Holders of PALISADE BIO, INC. - Common Stock, par value $0.01 per share (PALI) as of Q2 2025
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.